Polar Capital Holdings’s Intellia Therapeutics NTLA Stock Holding History

Polar Capital Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,725	Closed	-$264	–	370
2022 Q3	$264	Sell	4,725 -252,785	-98%	-$15.7M	﹤0.01%	363
2022 Q2	$13.3K	Hold	257,510	–	–	0.08%	173
2022 Q1	$18.7K	Buy	+257,510	New	+$21.8M	0.08%	172
2021 Q3	–	Sell	-94,624	Closed	-$15.3K	–	367
2021 Q2	$15.3K	Buy	+94,624	New	+$7.37M	0.07%	193

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Polar Capital Holdings's NTLA Position: Q4 2022 in Review

Polar Capital Holdings sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 4,725 shares — an estimated $264 sold.

Polar Capital Holdings first reported a position in NTLA in Q2 2021 and held it in 4 quarters. The position peaked at $18.7K in Q1 2022. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

Polar Capital Holdings reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
Polar Capital Holdings sold 4,725 Intellia Therapeutics shares in Q4 2022, an estimated $264.
Polar Capital Holdings first reported a position in Intellia Therapeutics in Q2 2021 and held it in 4 quarters.
Polar Capital Holdings's Intellia Therapeutics position peaked at $18.7K in Q1 2022.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Polar Capital Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.